PT-141 , scientifically known as Bremelanotide , is a synthetic analog of alpha-melanocyte-stimulating hormone (-MSH)
The interplay between herbal medicines and gut microbiota in metabolic diseases
Its reputation in research circles as a potent healing and protective agent is formidable
Ongoing large-scale prospective studies and post-marketing surveillance are needed to further refine risk estimates and inform evidence-based clinical guidance for patients at higher baseline risk
The popularity of GLP-1 agonists to treat obesity has been skyrocketing in recent months, leading to both shortages and price increases
As MBS leaderand Accomplish Health advisorJOHN MORTON puts it: Combining surgical approaches and GLP-1 receptor agonist therapy presents an opportunity to further improve outcomes for patients undergoing MBS. --- Review: Combining Medications With Bariatric Surgery to Treat Obesity To view or add a comment, sign in Compared with GLP-1 RAs, bariatric metabolic surgery was associated with lower rates of: All-cause mortality Major adverse cardiovascular events (MACE) Nephropathy Retinopathy These findings indicate that even with the availability of GLP-1 RAs, metabolic surgery remains superior to medical treatment for macrovascular and microvascular outcomes in patients with diabetes and obesity